Literature DB >> 6338469

Antifungal chemotherapy.

M H Koldin, G Medoff.   

Abstract

When the decision to treat a fungal infection is made, there are several antifungal agents available for use. AmB remains the first-line drug in the treatment of most systemic fungal infections. Miconazole should be used to treat patients who cannot tolerate AmB or who are infected with AmB-resistant organisms. Ketoconazole has a distinct advantage in that it is a relatively nontoxic oral agent and may prove very effective in treating non-life-threatening chronic fungal infections. Clinical experience with miconazole and ketoconazole is too limited at present to recommend them as first-line therapeutic agents, except in a limited number of clinical situations. 5-FC should only be used in combination with AmB to treat yeast infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6338469     DOI: 10.1016/s0031-3955(16)34319-x

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  2 in total

Review 1.  Amphotericin B nephrotoxicity.

Authors:  R Sabra; R A Branch
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 2.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.